![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005469/en/739014/5/teva_RGB_JPEG.jpg)
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
![Teva Announces Share Pricing Pending Actavis Generics Acquisition | Teva pharmaceuticals, Teva, Pharmaceutical industry Teva Announces Share Pricing Pending Actavis Generics Acquisition | Teva pharmaceuticals, Teva, Pharmaceutical industry](https://i.pinimg.com/736x/9d/fb/a3/9dfba3e1e469623d0a5ce8bd61d3978b--news.jpg)
Teva Announces Share Pricing Pending Actavis Generics Acquisition | Teva pharmaceuticals, Teva, Pharmaceutical industry
![J&J, Teva offer a whopping $48B combined to wrap opioid suits, but not all plaintiffs are on board | Fierce Pharma J&J, Teva offer a whopping $48B combined to wrap opioid suits, but not all plaintiffs are on board | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1571685528/teva1_1.jpg/teva1_1.jpg?VersionId=DZxWIUBep5WwbJo2nfwehxGzs6STVv3O)